Based on our Pharmacor advisory service entitled Gastric Cancer, Decision Resources is offering an exclusive analyst call entitled Decision Reversed – After a Preliminary Negative Appraisal, NICE Endorses Herceptin for the Treatment of HER2-Positive Gastric Cancer. Because this presentation features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.

Recorded live on Friday, October 15, 2010


This 15-minute analyst call, presented by Decision Resources Analyst Rachel Webster, D.Phil., answers the following questions:

• What factors led to NICE's preliminary negative appraisal for Herceptin in HER2-positive gastric cancer?
• Why did NICE reverse its decision and recommend Herceptin for HER2-positive gastric cancer? How did new data for a subpopulation of patients influence this decision?
• As compared to the United Kingdom, who will be eligible to receive Herceptin in the other four EU5 countries - France, Germany, Italy and Spain?
• In the world’s major pharmaceutical markets, what is Decision Resources’ sales forecast through 2019 for Herceptin in gastric cancer? 

Contact us to learn how you can purchase this service and access a recorded playback of this event.

Click here to view the invite.